Literature DB >> 16835321

Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.

Thomas Hiller1, Sven Poppelreuther, Frank Stubenrauch, Thomas Iftner.   

Abstract

We have analyzed E6 proteins of 19 papillomaviruses able to infect genital tissue with regard to their ability to degrade p53 and the thus far unknown immortalization potential of the genomes of human papillomaviruses (HPV) 53, 56, 58, 61, 66, and 82 in primary human keratinocytes. E6 proteins of HPV types 16, 18, 33, 35, 39, 45, 51, 52, 56, 58, and 66, defined as high-risk types, were able to induce p53 degradation in vitro, and HPV18-, HPV56-, and HPV58-immortalized keratinocytes revealed markedly reduced levels of p53. In contrast, the E6 proteins of HPV6 and 11 and HPV44, 54, and 61, regarded as possible carcinogenic or low-risk HPV types, respectively, did not degrade p53. Interestingly, the E6 proteins of HPV 53, 70, and 82 inconsistently risk classified in the literature were also found to induce p53 degradation. The genomes of HPV53 and 82 immortalized primary human keratinocytes that revealed almost absent nuclear levels of p53. These data suggest a strict correlation between the biological properties of certain HPV types with conserved nucleotide sequence (phylogeny), which is largely coherent with epidemiologic risk classification. HPV types 16, 18, 33, 35, 39, 45, 51, 52, 56, 58, and 66, generally accepted as high-risk types, behaved in our assays biologically different from HPV types 6, 11, 44, 54, and 61. In contrast, HPV70, regarded as low-risk type, and HPV53 or HPV82, with inconsistent described risk status, were indistinguishable with respect to p53 degradation and immortalization from prototype high-risk HPV types. This could imply that other important functional differences exist between phylogenetically highly related viruses displaying similar biological properties in tissue culture that may affect their carcinogenicity in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835321     DOI: 10.1158/1055-9965.EPI-05-0778

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

Review 1.  Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).

Authors:  Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

2.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

3.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

5.  Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes.

Authors:  Denise M Schütze; Jan M Kooter; Saskia M Wilting; Chris J L M Meijer; Wim Quint; Peter J F Snijders; Renske D M Steenbergen
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

6.  Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.

Authors:  Marcel Chris Conrady; Irina Suarez; Gergö Gogl; Desiree Isabella Frecot; Anna Bonhoure; Camille Kostmann; Alexandra Cousido-Siah; André Mitschler; JiaWen Lim; Murielle Masson; Thomas Iftner; Frank Stubenrauch; Gilles Travé; Claudia Simon
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

7.  Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.

Authors:  A T Hesselink; J Berkhof; M L van der Salm; A P van Splunter; T H Geelen; F J van Kemenade; M G B Bleeker; D A M Heideman
Journal:  J Clin Microbiol       Date:  2014-01-03       Impact factor: 5.948

Review 8.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

9.  Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity.

Authors:  Leiping Fu; Koenraad Van Doorslaer; Zigui Chen; Tutik Ristriani; Murielle Masson; Gilles Travé; Robert D Burk
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

10.  The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints.

Authors:  Weifang Zhang; Jing Li; Sriramana Kanginakudru; Weiming Zhao; Xiuping Yu; Jason J Chen
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.